DBV Technologies (NASDAQ:DBVT) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of DBV Technologies (NASDAQ:DBVT) from a sell rating to a hold rating in a research report released on Sunday.

Other equities research analysts have also recently issued reports about the company. Citizens Jmp increased their target price on DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a report on Wednesday, December 17th. Guggenheim reissued a “buy” rating and set a $51.00 price objective (up previously from $35.00) on shares of DBV Technologies in a research note on Wednesday, December 17th. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 29th. HC Wainwright set a $40.00 target price on shares of DBV Technologies in a research note on Thursday, December 18th. Finally, Cantor Fitzgerald set a $48.00 price target on shares of DBV Technologies in a research report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, DBV Technologies has an average rating of “Moderate Buy” and an average price target of $35.38.

DBV Technologies Stock Performance

Shares of NASDAQ:DBVT opened at $21.26 on Friday. The firm has a market capitalization of $853.80 million, a PE ratio of -4.11 and a beta of -0.98. DBV Technologies has a 52-week low of $3.82 and a 52-week high of $26.18. The firm has a fifty day moving average of $19.35 and a 200 day moving average of $14.46.

Insider Transactions at DBV Technologies

In other DBV Technologies news, major shareholder Bpifrance Epic sold 2,076,990 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $4.85, for a total value of $10,073,401.50. Following the completion of the transaction, the insider directly owned 8,595,472 shares in the company, valued at approximately $41,688,039.20. This represents a 19.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have sold 3,369,627 shares of company stock worth $15,489,908. 1.44% of the stock is currently owned by insiders.

Hedge Funds Weigh In On DBV Technologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vivo Capital LLC bought a new stake in shares of DBV Technologies during the 2nd quarter valued at $9,659,000. Adage Capital Partners GP L.L.C. purchased a new position in DBV Technologies during the 2nd quarter valued at about $9,659,000. MPM Bioimpact LLC bought a new stake in DBV Technologies during the second quarter worth about $9,649,000. Octagon Capital Advisors LP purchased a new stake in DBV Technologies in the second quarter worth about $9,315,000. Finally, UBS Group AG grew its holdings in DBV Technologies by 165,347.3% in the fourth quarter. UBS Group AG now owns 244,862 shares of the company’s stock worth $4,694,000 after purchasing an additional 244,714 shares during the period. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.